56/100Is ATAI-AtaiBeckley a buy?
Thursday 16 July 2026
Why now: ATAI is moving because Eli Lilly announced a definitive agreement to acquire the company, turning the near-term story into deal-close risk plus CVR milestone optionality. The timing edge is the market repricing around the disclosed cash consideration and the probabilities investors assign to the milestone payments.
Upside: From the current premarket print of $7.16, upside is primarily the spread to the $6.75 cash close plus any value the market assigns to the up to $2.50 CVR; the base cash leg offers limited upside from here, while the CVR is the only meaningful incremental optionality. If the stock trades below the cash consideration due to closing risk, the upside becomes the deal spread; if it trades above, the market is pricing in some CVR value and the upside is more constrained.
Risks: The key risk is deal risk: the merger can be delayed or fail due to shareholder or regulatory outcomes, which would likely remove today’s premium quickly. The second risk is CVR uncertainty, since milestone payments depend on future trial starts and regulatory approvals within defined timelines.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free, no credit card needed.
Scorecard
| Scorecard | 56/100 | |
|---|---|---|
| Company Detail | ATAI, AtaiBeckley Inc. | |
| Price as at 15 July 2026 | $5.36 | |
| Market cap | $2.0B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 6/20 | |
| Rev/EPS Momentum /20 | 3/20 | |
| Business Quality /15 | 10/15 | |
| Balance Sheet /15 | 12/15 | |
| Valuation /10 | 6/10 | |
| Industry Relative Strength /10 | 9/10 | |
| Macro / Sector Tailwind /10 | 10/10 | |
| Growth | ||
| Cash runway | 0.38 yr | |
| Revenue YoY | +1227.6% | |
| EPS YoY | -212.9% | |
| FCF YoY | -37.6% | |
| Gross margin | — | |
| Valuation & Trend | ||
| Trailing P/E | — | |
| Forward P/E | neg | |
| RSI (14d) | 59 | |
| vs 50d SMA | +20.8% | |
| Support cushion | −5.6% | |
| Sentiment | ||
| Wall Street verdict | Aligned | |
| News tone | Positive | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3, 2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis, Thursday 16 July 2026
Srinivas Rao has been Chief Executive Officer of AtaiBeckley Inc.
Michael Faerm became Chief Financial Officer effective March 9, 2026.
Gerd Kochendoerfer serves as Chief Operating Officer of AtaiBeckley Inc.
Receiver of capital expenditure: No, This is a drug developer without commercial products, so it is not a receiver of customer capital expenditure; funding comes from investors and, if applicable, partners.
Main customers
- Clinical trial sites and investigators (They deliver patient enrollment and trial execution; they are operational counterparties rather than revenue customers.)
- Regulated healthcare systems and providers (future) (If approved, payers and providers would be the economic customers, but there is no commercial revenue base today.)
Notable contracts
- Agreement and Plan of Merger with Eli Lilly and Company, $6.75 per share in cash at closing plus a contingent value right of up to $2.50 per share tied to development and regulatory milestones (Transaction expected to close in Q3 2026, subject to shareholder approval and customary regulatory conditions.)
- AtaiBeckley is a clinical-stage mental health drug developer with a lead depression program and additional pipeline shots on goal, but it remains a pre-revenue, trial-outcome-driven business.
- The long-term value used to be about whether its lead programs could progress into and through pivotal trials with acceptable safety and durable outcomes.
- As of today, the practical 1+ year ownership case is largely replaced by merger completion and whether the contingent milestone structure ultimately pays out.
Show 4 headlines from the last 7d
Scores 56 out of 100, a mixed overall grade. Sector fit, relative strength versus its industry, and balance sheet scored highest. Business quality and valuation were fair but not standout drivers. Chart setup and earnings trend weighed on the total. Score is capped because the stock is now primarily a merger-arbitrage situation after a definitive acquisition agreement was announced, which limits fundamental “multi-year ownership” upside from here and makes the outcome mainly about deal close timing and CVR milestone probability rather than stand-alone execution.
Component scores are on the scorecard above.
- AtaiBeckley is still a clinical-stage company with ongoing net losses and no durable product revenue base, so fundamentals are primarily balance sheet runway and pipeline execution rather than earnings power.
- In its first quarter 2026 update, the company reported $209.9 million of cash, cash equivalents, and short-term securities and said it expected funding runway into 2029, alongside higher operating spending as late-stage preparation advanced.
- The company’s key value drivers are clinical and regulatory: BPL-003 has been positioned for pivotal studies, VLS-01 has Phase 2 topline data expected in Q4 2026, and the overall profile remains binary because any safety signal, efficacy miss, or trial delay can sharply change the valuation.
Cash runway: 0.38 yr ($43M cash ÷ $114M/yr burn, latest fiscal year).
Upcoming (1-6 months)
- Shareholder vote and regulatory clearance progress for the Lilly acquisition, with the companies guiding to a Q3 2026 close.
Ongoing
- How the market prices the CVR over time, which reflects changing probabilities for Phase 3 initiation and eventual approvals of BPL-003 and VLS-01.
Risks
- Merger delay or termination risk, including unexpected regulatory issues, competing bids, litigation, or shareholder dynamics that change the expected close timeline or terms.
- CVR may ultimately pay little or nothing if timelines slip, trials do not start as required, or approvals and scheduling actions do not occur within the defined windows.
Breaks the thesis
- A break in the deal thesis would be any credible announcement that the merger is not proceeding on the stated terms or that required approvals are not expected, which would likely remove the takeout premium and reset the stock to a stand-alone biotech valuation.